fashion -WSS

fashion

author：focus 2025-08-11 11:45:38 - browse：6

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

Report cites 'urgent' need to recruit more diverse clinical trial participants

Why you shouldn’t ask, “What country has the best health care?”

Bernie Sanders is gearing up to subpoena pharma CEOs

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Report cites 'urgent' need to recruit more diverse clinical trial participants

Latigo launches with $135 million for Vertex

knowledge

fashion

entertainment

Supreme Court strikes down use of affirmative action

Artificial intelligence use in health care faces greater scrutiny in 2024

Wildfire smoke exposes gaps in outdoor worker protections

Why don't Americans have at

Psychedelics group wrestles with new pharma identity

Congress might make insulin pumps more accessible to the blind

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

In age of alternative facts, a scholarly course on calling out crap

Having children helps parents live longer, especially after age 80

leisure time

FTC sues over Novant Health acquisition of two N.C. hospitals

How generative AI ratchets up security threats for health systems

Biogen walks away from Aduhelm, years after polarizing approval

Tome Biosciences co

Bernie Sanders is gearing up to subpoena pharma CEOs

The Affordable Care Act has saved billions in health care costs

knowledge

hotspot

entertainment

focus